Japanese Ono Pharmaceutical Transfers Clinical Trial Division to U.S.
This article was originally published in PharmAsia News
TOKYO - Beginning May 1, Ono Pharmaceuticals will transfer its division for coordination of clinical studies in Japan, the U.S. and Europe, to its Lawrenceville, New Jersey wholly-owned subsidiary. Ono's division for promotion of tie-ups with venture businesses and universities will also move to Ono Pharma USA, the Osaka, Japan-based company announced April 21. The reorganization is aimed at facilitating the company's approval for new drugs in the U.S., and upgrading collaboration on clinical studies in its three key markets. Company public relations head Kinya Morimoto told PharmAsia News Ono has been planning for a number of years to launch the approval process for its drugs in the three markets from the U.S. "We have relaunched Ono Pharma USA as our base for global development," Morimoto said. The approval process lag time in Japan did not factor in Ono's decision to move. Rather, the company has set as first priority doing clinical studies and getting approval for drugs in buyer countries, Morimoto explained. "As our development project unfolds, we plan to shift personnel to the U.S.," he said
You may also be interested in...
TOKYO - Ono Pharma's drug portfolio is "going from maturity to decline," according to a Bank America Merrill Lynch analyst, but there are signs that in-licensed products from Merck, particularly antiemetic Emend (aprepitant), could bring new life to the company
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).